The group’s principle activity is to improve the treatment of serious lung diseases through the development of novel, site-specific liposomal drug products. The group’s products include Arikace, Cisplatin Lipid Complex(Primary Lung Cancer), Cisplatin Lipid Complex(Osteosarcoma lung metastases) and "Anti-Infective 2". The group operates from United States.
